Ibrutinib in Relapsed Nodular Lymphocyte-predominant Hodgkin Lymphoma (NLPHL)

Inclusion Criteria (key criteria): 1. Histologically proven relapsed nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) as confirmed by expert review 2. Age at entry 18-99 years 3. ECOG status 0-2 4. Absolute leukocyte count \> 2.500/mm3 5. Absolute neutrophil count \> 1.000/mm3 independent of growth factor support 6. Platelet count \> 100.000/mm3 or \> 50.000/mm3 in case of bone marrow involvement independent of transfusion support in either situation 7. GPT and GOT ≤ 3 x upper limit of normal (ULN) Exclusion Criteria (key criteria): 1. Classical HL (cHL) or composite lymphoma 2. Known central nervous lymphoma 3. Prior Btk inhibitor treatment 4. Life expectancy \< 3 months 5. Major surgery within 4 weeks of study inclusion 6. History of stroke or intracranial hemorrhage within 6 months prior to the first study drug 7. Current anticoagulation with warfarin or equivalent vitamin K antagonists